ClinicalTrials.gg
Not yet recruitingNCT06448130Updated Jun 7, 2024

Henagliflozin's Impact on Prediabetes Remission

A Phase 4 interventional study of Henagliflozin 5mg and Henagliflozin 10mg in PreDiabetes, Prediabetic State and Type 2 Diabetes, sponsored by Shandong Provincial Hospital. Not yet recruiting at 50 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-07.

Sponsored by Shandong Provincial Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
984
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Prediabetic State with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Prediabetic State · China.

Planned enrollment
9th of 44
984 · median 160
Started
2024
with 5 others
Phase 4
8 of 51
3 open now
Primary completion
2026-12
later than 8 of 24 live
Registered
32nd of 51
by date
Lead sponsor
3 of 51
Shandong Provincial Hospital

Among the 51 studies in Prediabetic State with a site in China, this one is the 9th largest by planned enrollment of the 44 interventional ones that give a count, is one of 6 that started in 2024, is one of 8 in phase 4, reaches primary completion later than 8 of the 24 other live ones, and was the 32nd registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

24 of the 51 studies in Prediabetic State with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Prediabetic State with a site in China, or all of them as a file.
02

Study summary

This clinical trial evaluates the effectiveness of Henagliflozin combined with lifestyle interventions for managing patients with prediabetes. As global prediabetes rates rise, increasing the risk of diabetes and vascular issues, addressing treatment gaps is essential. Henagliflozin, a novel SGLT2 inhibitor developed in China, aims to improve glucose control and metabolic health when paired with lifestyle changes.

The study's primary objectives include: assessing whether Henagliflozin can achieve normoglycemia in prediabetic patients after 6 months of treatment.

The trial will compare three groups (Henagliflozin 5mg, 10mg, and a placebo), focusing on efficacy and safety. Participants, assigned randomly, will undergo a 6-month treatment phase and an 18-month follow-up. Regular health assessments will monitor glucose levels, metabolic health, and risks of major complications like cardiovascular events and microvascular diseases, with additional evaluations of C-peptide and insulin changes.

Structured as a multicenter, randomized, double-blind, placebo-controlled study, it involves 984 prediabetic adults across 50 medical institutions in China. This comprehensive approach could redefine prediabetes management by integrating drug therapy with lifestyle modifications.

Read the detailed description

This research is launched in light of the global surge in prediabetes, a condition that markedly increases the risk of developing type 2 diabetes and related vascular complications. While lifestyle modifications are the frontline defense against prediabetes, the variability in individual responses often requires the integration of pharmacological treatments. Studies have shown that drugs such as metformin, acarbose, SGLT2 inhibitors, GLP-1 agonists, GIP/GLP-1 receptor agonists, thiazolidinediones, and orlistat effectively curb the progression to diabetes. Yet, there remains a gap in specific research addressing the intervention needs of the prediabetic population in China.

Currently, acarbose is the only drug approved in the Chinese market for treating patients with impaired glucose tolerance, highlighting a limited range of therapeutic options for prediabetes. SGLT2 inhibitors, as a newer class of hypoglycemic agents, have demonstrated significant promise in reducing major cardiovascular events in high-risk patients with type 2 diabetes, enhancing outcomes in heart failure, and providing renal protection. However, there is a scarcity of large-scale, prospective studies on the impact of SGLT2 inhibitors in prediabetes. Henagliflozin, the first original SGLT2 inhibitor developed in China and launched on December 31, 2021, is being studied to assess its effectiveness combined with lifestyle interventions in the prediabetic demographic, aiming to fill a crucial void in the current treatment paradigm.

This study aims to assess the combined benefits of Henagliflozin and lifestyle modifications in managing prediabetes. The investigators conducted a two-year prospective, randomized, double-blind, placebo-controlled trial across 50 medical institutions in various provinces of China. It is planned to enroll 984 adult prediabetic patients who had not previously been treated with antidiabetic medications. Participants meeting inclusion criteria were randomly assigned to one of three groups: Henagliflozin 5mg, Henagliflozin 10mg, or placebo. The intensive intervention phase, consisting of pharmacotherapy combined with lifestyle changes, lasted for 6 months, followed by an 18-month follow-up period focusing solely on lifestyle interventions.

The primary endpoint is the proportion of participants achieving normoglycemia after 6 months of intervention, with subsequent assessments at 12 months. Secondary endpoints include short-term (0-12 months) and long-term (12-24 months) changes in glucose control, metabolic indicators such as body weight, body mass index (BMI), body fat content, waist and hip circumference, lipid profiles, blood pressure, serum uric acid levels, hepatic steatosis, and carotid intima-media thickness. Exploratory outcomes encompass changes in C-peptide and insulin levels from baseline to 6 months, and the risk of major adverse cardiovascular events (MACE) from baseline to 24 months and beyond.

03

Conditions studied

  • PreDiabetes
  • Prediabetic State
  • Type 2 Diabetes
  • Glucose Metabolism Disorders

Keywords

  • Prediabetes management
  • Henagliflozin
  • SGLT2 inhibitors
  • Lifestyle interventions
  • Type 2 diabetes prevention
  • Glucose Metabolism Disorders
  • Metabolic Diseases
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between the ages of 18 and 65 years;
  2. Individuals without hypoglycemic therapy before, including hypoglycemic drugs or traditional Chinese medicine formulations with hypoglycemic effects;
  3. Prediabetic patients as defined by Expert Consensus on Intervention for Prediabetes in Chinese Adults, 2023 Edition:1)Fasting plasma glucose (FPG) between 6.1 and 7.0 mmol/L and/or 2-hour postprandial glucose (2h-PPG) between 7.8 and 11.1 mmol/L; 2)And/or between 5.7% and 6.5%;
  4. Individuals willing to provide written and can comply with study procedures and follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Allergic to Henagliflozin;
  2. Previously diagnosed with diabetes;
  3. ≥ 6.5% or FPG ≥ 7.0 mmol/L or PPG ≥ 11.1 mmol/L;
  4. Use of GLP-1 receptor agonists, orlistat, or other weight-reducing drugs in the past 3 months;
  5. Fluctuation in weight by 5% or more in the past month;
  6. Use of drugs affecting glucose synthesis, absorption, or metabolism, such as (e.g., prednisone, dexamethasone), , growth hormone, hormonal replacement therapy (estrogen and progesterone), (e.g., cyclosporine A, tacrolimus), anti-tuberculosis drugs (e.g., isoniazid, rifampicin);
  7. Untreated hyperthyroidism or hypothyroidism, excluding those with normal thyroid function after treatment;
  8. Persistently uncontrolled hypertension (used antihypertensive drugs but was not effectively controlled in the 3 months prior to enrollment) or currently use 3 or more antihypertensive drugs (including diuretics);
  9. Assessed by the investigator to be at high risk of genitourinary system infections, such as history of recurrent urinary tract infections or reproductive system infections, long-term placement of urinary catheters, or history of urological surgery;
  10. Other obesity caused by endocrine disorders, such as Cushing's syndrome;
  11. (ALT) or aspartate aminotransferase (AST) levels > 3 times of the (UNL);
  12. less than 30 mL/min/1.73 m2, severe kidney damage, end-stage renal disease or requiring dialysis;
  13. Significant cardiovascular diseases including myocardial infarction, congestive heart failure (≥grade III ), ≤40%, or cerebrovascular accidents;
  14. Impaired consciousness and various mental health disorders;
  15. Malignant tumors and other serious illnesses;
  16. Pregnant or breast-feeding or planning pregnancy within 24 months;
  17. Enrolled in another clinical trial currently or within the 3 months prior to enrollment;
  18. Identified by the investigator that lacks sufficient motivation to continue the long-term clinical trial (e.g., out-of-town study, work plan, need to care for family members), or considered prefer to withdraw from the trial for non-medical reasons (such as social issues).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
984 participants (estimated)

Study arms

  • Experimental
    Henagliflozin5mg + lifestyle intervention

    Henagliflozin 5mg+ placebo 10mg po qd + lifestyle intervention for 6 months

    Drug: Henagliflozin 5mg

  • Experimental
    Henagliflozin10mg+ lifestyle intervention

    Henagliflozin 10mg+ placebo 5mg po qd + lifestyle intervention for 6 months

    Drug: Henagliflozin 10mg

  • Placebo comparator
    placebo+ lifestyle intervention

    placebo 10mg + placebo 5mg po qd + lifestyle intervention for 6 months

    Drug: Placebo

Interventions

  • DrugHenagliflozinStudies of HenagliflozinHenagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Henagliflozin 5mg + lifestyle intervention

    Also known as: lifestyle intervention

  • DrugHenagliflozinStudies of HenagliflozinHenagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Henagliflozin 10mg+ lifestyle intervention

    Also known as: lifestyle intervention

  • DrugPlacebo

    Placebo+ lifestyle intervention

    Also known as: lifestyle intervention

06

What researchers measure

Primary outcomes

  1. Normoglycemia Achievement Rates Post-6-Month Intervention

    This measure assesses the proportion of participants who achieve normoglycemia from the end of a 6-month intervention until the 12-month assessment point. Normoglycemia is defined as fasting plasma glucose (FPG) less than 6.1 mmol/L and 2-hour post-prandial glucose (2h-PPG) less than 7.8 mmol/L. The measure includes rates of sustained remission (normal glycemic status lasting more than 6 months post-medication cessation), partial remission (lasting 3-6 months), and temporary remission (lasting less than 3 months).

    Time frame: From 6 months post-intervention to 12 months

Secondary outcomes

  1. Blood Glucose Control Normalization

    Proportion and duration of normalization of blood glucose levels within 24 months in the three study groups.

    Time frame: From 6 months post-intervention to 24 months

  2. Incidence of New-Onset Type 2 Diabetes

    Incidence of new-onset type 2 diabetes within 24 months in the three study groups.

    Time frame: From 0 to 24 months

  3. Changes in HbA1c Levels

    Changes in HbA1c levels over the 24-month period in the three study groups.

    Time frame: From 0 to 24 months

  4. Impact of Glycemic Status at 12 Months

    Impact of glycemic status at 12 months on subsequent reversal to normoglycemia and risk of new-onset type 2 diabetes during the 12-24 month follow-up period in the three study groups.

    Time frame: From 12 months to 24 months

  5. Changes in blood pressure over 24 Months

    Changes in systolic and diastolic blood pressure in the three study groups over 24 Months.

    Time frame: From 0 to 24 months

  6. Changes in serum uric acid levels over 24 Months

    Changes in serum uric acid levels in the three study groups over 24 Months.

    Time frame: From 0 to 24 months

  7. Changes in hepatic steatosis over 24 Months

    Changes in hepatic steatosis assessed by abdominal ultrasound in the three study groups over 24 Months.

    Time frame: From 0 to 24 months

  8. Changes in carotid intima-media thickness over 24 Months

    Changes in carotid intima-media thickness measured by carotid ultrasound in the three study groups over 24 Months.

    Time frame: From 0 to 24 months

  9. Changes in Total Cholesterol (TC) over 24 Months

    Measurement of Total Cholesterol (TC) levels in millimoles per liter (mmol/L) using standardized laboratory procedures. Fasting blood samples will be collected at multiple time points within the 24-month period to assess changes over time.

    Time frame: From 0 to 24 months

  10. Changes in Triglycerides (TG) over 24 Months

    Measurement of Triglycerides (TG) levels in millimoles per liter (mmol/L) using standardized laboratory procedures. Fasting blood samples will be collected at multiple time points within the 24-month period to assess changes over time.

    Time frame: From 0 to 24 months

  11. Changes in Low-Density Lipoprotein Cholesterol (LDL-c) over 24 Month

    Measurement of Low-Density Lipoprotein Cholesterol (LDL-c) levels in millimoles per liter (mmol/L) using standardized laboratory procedures. Fasting blood samples will be collected at multiple time points within the 24-month period to assess changes over time.

    Time frame: From 0 to 24 months

  12. Changes in High-Density Lipoprotein Cholesterol (HDL-c) over 24 Months

    Measurement of High-Density Lipoprotein Cholesterol (HDL-c) levels in millimoles per liter (mmol/L) using standardized laboratory procedures. Fasting blood samples will be collected at multiple time points within the 24-month period to assess changes over time.

    Time frame: From 0 to 24 months

  13. Changes in Body Weight over 24 Months

    Measurement of body weight in kilograms (kg) at multiple time points within the 24-month period.

    Time frame: From 0 to 24 months

  14. Changes in Body Mass Index (BMI) over 24 Months

    Calculation of BMI in kg/m² using the formula: weight (kg) / (height (m)²), measured at multiple time points within the 24-month period.

    Time frame: From 0 to 24 months

  15. Changes in Body Fat Content over 24 Months

    Measurement of body fat content as a percentage (%) of total body weight at multiple time points within the 24-month period.

    Time frame: From 0 to 24 months

  16. Changes in Waist Circumference over 24 Months

    Measurement of waist circumference in centimeters (cm) at multiple time points within the 24-month period.

    Time frame: From 0 to 24 months

  17. Changes in Hip Circumference over 24 Months

    Measurement of hip circumference in centimeters (cm) at multiple time points within the 24-month period.

    Time frame: From 0 to 24 months

  18. Changes in C-peptide Levels over the First 6 Months

    Measurement of C-peptide levels in nanomoles per liter (nmol/L) at multiple time points within the 6-month period.

    Time frame: From 0 to 6 months

  19. Changes in Insulin Levels over the First 6 Months

    Measurement of insulin levels in milliunits per liter (mU/L) at multiple time points within the 6-month period.

    Time frame: From 0 to 6 months

  20. Major Adverse Cardiovascular Events

    Major Adverse Cardiovascular Events (MACE) in the three study groups over 0-24 months.

    Time frame: From 0 to 24 months

  21. Risk of Retinal Diseases

    Risk of retinal diseases (e.g., diabetic retinopathy) in the three study groups over 0-24 months.

    Time frame: From 0 to 24 months

  22. Risk of Renal diseases

    Risk of renal diseases (e.g., diabetic nephropathy/chronic kidney disease) in the three study groups over 0-24 months.

    Time frame: From 0 to 24 months

07

Study locations

50 sites
08

References and documents

Individual participant data

Plan to share: Undecided — We have opted for 'Undecided' regarding the sharing of individual participant data (IPD) at this stage. Our decision is pending as we are currently engaged in ongoing discussions and evaluations regarding the most appropriate approach to IPD sharing for our research. Factors such as ethical considerations, data sensitivity, and regulatory requirements are being carefully assessed. We aim to reach a well-informed decision in due course and will update our IPD sharing plan accordingly. Thank you for your understanding as we navigate through this process.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for Dec 2026, 30 months later.

Of 30 phase 4 interventional studies under Prediabetic State, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 47. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
Jun 7, 2024
StartEst.
Jun 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jun 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06448130
Lead sponsor
Shandong Provincial Hospital
Responsible party
Jia-jun Zhao (Principal Investigator, Shandong Provincial Hospital) — Principal investigator
First posted
Jun 7, 2024
Start date
Jun 2024 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 7, 2024

Study contacts

Xiude Fan, MD&PhD
Contact
fanxiudexjtu@163.com
+8613186067538
Junming Han, PhD
Contact
hanjunming@sdfmu.edu.cn
+8615610140319

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Henagliflozin

Start the discussion